10-Q: STAAR Surgical Reports Q3 2024 Results: ICL Sales Drive Revenue Growth

STAAR Surgical Company's Q3 2024 results show a 10.3% increase in net sales driven by a 9.9% rise in ICL sales, despite some foreign currency headwinds.

Summary

• STAAR Surgical Company reported a 10.3% increase in net sales for the three months ended September 27, 2024, reaching $88.59 million, compared to $80.31 million in the same period of 2023.
• The growth was primarily driven by a 9.9% increase in sales of Implantable Collamer Lenses (ICLs), which totaled $89.10 million.
• Gross profit for the quarter increased by 7.6% to $68.49 million, but the gross profit margin decreased to 77.3% due to higher per-unit costs from reduced production volume.
• Operating income decreased to $5.68 million from $6.30 million in the prior year's quarter.
• Net income for the quarter was $9.98 million, or $0.20 per diluted share, compared to $4.82 million, or $0.10 per diluted share, in the same period last year.
• For the nine months ended September 27, 2024, net sales increased by 7.6% to $264.95 million, with ICL sales up 8.5% to $265.62 million.
• The company's cash and cash equivalents decreased to $164.00 million from $183.04 million at the end of 2023, while investments available for sale increased to $71.96 million from $49.39 million.
• The company's effective tax rate for the three months ended September 27, 2024 was 24.2% and 34.1% for the nine months ended September 27, 2024.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and a significant increase in net income, but there are some concerns about decreasing gross profit margins and a decrease in cash. Overall, the sentiment is positive but with some caution.

Positives

• Net sales increased by 10.3% in Q3 2024, indicating strong demand for the company's products.
• ICL sales, the company's primary revenue driver, grew by 9.9% in Q3 2024 and 8.5% for the nine months ended September 27, 2024.
• Net income increased significantly to $9.98 million in Q3 2024, compared to $4.82 million in the same period last year.
• The company's investments available for sale increased by $22.56 million since the end of 2023.
• The company has a strong cash position with $164.00 million in cash and cash equivalents.

Negatives

• Gross profit margin decreased to 77.3% in Q3 2024, due to higher per-unit costs from reduced production volume.
• Operating income decreased to $5.68 million in Q3 2024 from $6.30 million in Q3 2023.
• Cash and cash equivalents decreased by $19.04 million since the end of 2023.
• Foreign currency changes unfavorably impacted net sales by $0.3 million in Q3 2024 and $2.6 million for the nine months ended September 27, 2024.

Risks

• The company's future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of pre-tax income.
• The company's cash flow from operating activities may fluctuate in future periods due to various factors, including fluctuations in operating results, working capital needs, capital expenditures, and capital deployment decisions.
• The company is subject to risks and uncertainties described in their Annual Report on Form 10-K, which could materially adversely affect their business, financial condition, or operating results.
• The company is involved in various legal proceedings and other matters arising in the normal course of business, which could lead to significant financial harm.

Future Outlook

The company expects that cash flow from operating activities may fluctuate in future periods as a result of a number of factors, including fluctuations in operating results, working capital needs, capital expenditures, and capital deployment decisions. Future capital requirements will depend on many factors including the company's growth rate in net sales, the timing and extent of spending to support the growth strategy, the expansion of selling and marketing activities, the timing of introductions of new products, as well as global macroeconomic factors.

Management Comments

• Management believes that there have been no significant changes during the nine months ended September 27, 2024 to the items that were disclosed as critical accounting estimates in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Annual Report on Form 10-K for the fiscal year ended December 29, 2023.
• Management believes that the company's sources of liquidity will be sufficient to meet anticipated cash needs for at least 12 months from the issuance date of the financial statements.

Industry Context

The company operates in the ophthalmic surgical product market, specifically focusing on implantable lenses for refractive surgery. The results reflect the company's continued focus on ICLs as a primary product, with a phase-out of cataract IOL sales. The growth in ICL sales indicates a positive trend in the adoption of this technology in the refractive surgery market.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, STAAR Surgical's focus on ICLs positions it in the premium segment of the refractive surgery market, which is generally characterized by higher margins and a focus on advanced technology.
• The company's gross profit margin of 77.3% for the quarter is relatively high, but the decrease from 79.2% in the prior year's quarter indicates potential challenges in managing production costs.
• The company's growth in ICL sales is a positive indicator, as this product is a key differentiator in the market.
• The company's performance should be compared to other companies in the ophthalmic surgical device market, such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb, to assess its relative position and growth trajectory.

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business, which may relate to contractual rights and obligations, employment matters, or claims of product liability.

Stakeholder Impact

• Shareholders will likely view the increased net income and revenue growth positively.
• Employees may benefit from the company's growth and financial stability.
• Customers will continue to have access to the company's products and services.
• Suppliers will continue to have a business relationship with the company.
• Creditors will likely view the company's financial position as stable.

Next Steps

• The company will continue to focus on driving awareness of the ICL procedure and the clinical benefits of their ICLs.
• The company will continue to provide surgeon training, support and education, particularly in newer markets.
• The company will continue to monitor and adjust their effective income tax rate based on various factors.

Key Dates

Keywords

ICL, Implantable Collamer Lenses, Ophthalmic Surgery, Refractive Surgery, Net Sales, Gross Profit, Operating Income, Net Income, Financial Results, Quarterly Report